WAKEFIELD, Mass., Nov. 4, 2025 /PRNewswire/ -- Odyssey, a leading provider of integrated defense capabilities and technologies, announced today it...
In this free webinar, learn how to recognize and address common blind spots in clinical trial imaging strategy. Attendees will...
Collaboration Advances Local Regulatory Pathway for AI-Enabled ECG Diagnostics to Address the Growing Cardiovascular Disease Burden in Jamaica TORONTO, ON...
New FDA feedback confirms clinical pathway for fixed multi-phage cocktail BX011, expanding development into diabetic foot infections (DFI) and unlocking...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., Nov....
MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company...
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin...
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual...
New NIH grant awards $2.5 million over 5 years for mechanistic studyBURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE)...
New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life’s unique antibody...
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage...
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today...
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib...
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation TechnologyExpert consensus predicts integration of...
DiaSafe™ technology for non-invasive DFU risk assessment and early intervention*The DFU treatment market is estimated to be approximately$10 billion globally1Rosh Pina,...
MIAMI, Nov. 3, 2025 /PRNewswire/ -- Sitero, a technology-enabled Clinical Research Organization (CRO), today announced it has acquired the AI...
- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and...
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...